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Abstract
Limited data exist on Candida endocarditis (CE) outcome in the era of new antifungals. As early diagnosis of CE remains difficult, non-cul-
ture-based tools need to be evaluated. Through the French prospective MYCENDO study (2005–2007), the overall characteristics and risk
factors for death from CE were analysed. The contribution of antigen detection (mannan/anti-mannan antibodies and (1,3)-b-D-glucans)
and molecular tools was evaluated. Among 30 CE cases, 19 were caused by non-albicans species. Sixteen patients (53%) had a predisposing
cardiac disease, which was a valvular prosthesis in ten (33%). Nine patients (30%) were intravenous drug users; none of them had right-
sided CE. Among the 21 patients who were not intravenous drug users, 18 (86%) had healthcare-associated CE. Initial therapy consisted of
a combination of antifungals in 12 of 30 patients (40%). Thirteen patients (43%) underwent valve replacement. The median follow-up was
1 year after discharge from hospital (range, 5 months to 4 years) and hospital mortality was 37%. On univariate analysis, patients aged
‡60 years had a higher mortality risk (OR 11, 95% CI 1.2–103.9; p 0.024), whereas intravenous drug use was associated with a lower risk
of death (OR 0.12, 95% CI 0.02–0.7; p 0.03). Among 18 patients screened for both serum mannan/anti-mannan antibodies and (1,3)-b-D-
glucans, all had a positive result with at least one of either test at CE diagnosis. Real-time PCR was performed on blood (SeptiFast) in 12 of
18, and this confirmed the blood culture results. In conclusion, CE prognosis remains poor, with a better outcome among younger patients
and intravenous drug users. Detection of serum antigens and molecular tools may contribute to earlier CE diagnosis.
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Introduction
Candida endocarditis (CE) is rare, accounting for <2% of all
infective endocarditis cases [1–3], and complicates
candidaemia in up to 17.7% of patients when transoesophageal
echocardiography (TEE) is systematically performed (Fernan-
dez Cruz et al., 50th ICAAC, 2010, Abstract K-2172). Previ-
ously observed predominantly in intravenous drug users, it
now occurs in the healthcare-associated setting, affecting
patients at risk for invasive fungal infections [1,2,4–7]. Recent
hospital mortality rates are still as high as 30–47% [1,2]. The
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most recent guidelines for the treatment of CE recommend
an amphotericin B-based or echinocandin-based regimen, with
or without flucytosine, followed by fluconazole for susceptible
organisms, in combination with valve replacement. If surgery
is contraindicated, chronic antifungal suppression is recom-
mended. However, data on the long-term outcome of CE are
very scarce, as no large prospective study focusing specifically
on CE has yet been conducted. Therefore, the guidelines are
mainly based on anecdotal case reports, case series, and clini-
cal experience [8]. We conducted a 27-month prospective
study in France to determine the current characteristics, risk
factors for death and long-term prognosis of CE, in addition
to the diagnostic contribution of fungal antigen detection and
molecular tools.
Materials and Methods
Clinical sample and data collection
The prospective MYCENDO study on fungal endocarditis
was conducted in France between 1 January 2005 and 31
March 2007. Infectious disease, cardiology, internal medicine,
intensive-care and paediatric specialists, cardiovascular sur-
geons and microbiologists of all university and general hospi-
tals were informed about the study by their scientific
societies. Anonymous data were collected in centres and
then validated by the MYCENDO scientific committee. Diag-
nostic and therapeutic management of individual cases was
performed in each participating hospital according to local
recommendations. In addition, all fungal isolates were analy-
sed at the French National Reference Centre for Mycoses
and Antifungals (Institut Pasteur, Paris); serum samples were
sequentially collected for detection of fungal antigens at the
University of Lille, blood samples were collected for detec-
tion of fungal DNA at University of East Paris Cre´teil, and
valvular samples were sent to Georges Pompidou Hospital,
Paris. Control sera were collected from six patients with
definite bacterial endocarditis. The study was approved by
the Comite´ de Protection des Personnes, Hoˆpital Necker,
Paris; #04-10-05, and promoted by the Institut Pasteur.
Definitions
All patients who met the criteria for definite or possible CE
were enrolled [9]. In accordance with previously published
criteria [9,10], CE was definite if culture and/or histology of
cardiac material or embolic tissue demonstrated Candida spe-
cies, or if there was the combination of persistently positive
blood cultures for Candida species and evidence of endocar-
dial involvement on echocardiogram; CE was possible in
cases where there were positive blood cultures for Candida
species and a predisposing heart condition, but no evidence
of endocardial involvement on the echocardiogram.
The date of CE diagnosis was defined as the day of the
first echocardiogram suggestive of endocarditis (n = 29) or
the first day of blood culture positivity in a patient with ven-
tricular assist device infection. Median time to diagnosis was
the number of days elapsed between the first clinical symp-
toms of CE and diagnosis.
Cases of CE were classified as either healthcare-associated
or community-associated, according to previously defined
criteria [11]. The indications for surgery were classified as
‘infectious’, ‘cardiac’, or ‘embolic’ [12].
The portal of entry was determined on the basis of com-
patible clinical, microbiological and/or radiographic features
and the isolation of the same Candida species from this pre-
sumed source of infection, except for skin, which was con-
sidered as the portal of entry in intravenous drug users
when no alternative source of infection was found after care-
ful examination. If the clinical data were ambiguous, the por-
tal of entry was categorized as ‘undetermined’. Myocardial
abscess and pacemaker lead infection were defined as previ-
ously reported [13,14].
At the time of death, CE was considered to be ‘ongoing’ in
the presence of otherwise unexplained fever of ‡38C, per-
sistent positive blood cultures for Candida species, new vascu-
lar phenomena [9], and/or the persistence of other major
criteria [9]. Otherwise, it was considered to be ‘controlled’.
Mycological methods
Species identification and antifungal susceptibility determina-
tion. All isolates were identified to the species level by the
use of carbon assimilation profiles (ID32C; Biome´rieux,
Marcy-l’Etoile, France). In vitro susceptibility testing was per-
formed according to EUCAST procedures [15]. Fluconazole,
voriconazole, flucytosine, caspofungin [16] and amphoteri-
cin B were tested as previously described [17,18]. The
thresholds defined by EUCAST were used for fluconazole
[19] and voriconazole [20]. MICs ‡8 mg/L were considered
to be high for flucytosine [21].
Detection of serum (1,3)-b-D-glucans. Serum samples were
diluted in glucan-free reagent-grade water (Fungitell assay;
Associates of Cape Cod, Falmouth, MA, USA). Interpretation
of (1,3)-b-D-glucan values was as follows: <60 pg/mL,
negative; 60–79 pg/mL, indeterminate; >80 pg/mL, positive.
Detection of serum mannan and anti-mannan antibodies.
Mannan and anti-mannan antibodies were measured with
commercialized tests (Platelia Candida Ag and Ab; Bio-Rad,
Marne-la-Coquette, France) [22]. The cut-offs were those
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proposed by the manufacturer: positive value, 0.5 ng/mL for
mannan and 10 AU/mL for anti-mannan.
Detection of fungal DNA in blood samples and in surgical cardiac
material. DNA extraction and amplification from blood sam-
ples were performed with the SeptiFast Prep Kit and the Septi-
Fast Kit (Roche Diagnostics, Mannheim, Germany). The results
were expressed as cycle threshold values. The higher the cycle
threshold, the lower the microbiological DNA burden.
DNA was extracted from excised cardiac tissue with the
QIAmp Tissue kit (Qiagen, Courtaboeuf, France), according
to the manufacturer’s instructions, with some modifications:
grinding of the biopsy specimens was performed with the
MagNA Lyser instrument (Roche Diagnostics), and lysis was
improved by five successive heat shocks. PCR amplification
followed by sequencing was performed with primers ITS1,
ITS3, and ITS4 [23,24], spanning the transcribed intergenic
spacers ITS1 and ITS2.
Statistical analysis
Characteristics were analysed as medians and range for con-
tinuous variables and as percentages for discrete variables.
Univariate analysis was based on the chi-square test or Fish-
er’s exact test for discrete variables. Continuous variables
were compared by use of the Mann–Whitney test. All signifi-
cance tests were two-sided, and p-values <0.05 were consid-
ered to be significant. The survival time was defined as the
interval between diagnosis of CE and death or the last follow-
up visit in patients who remained alive. Survival differences
were compared by use of the log-rank test, and survival
curves were calculated with the Kaplan–Meier method (cen-
soring at 24 months two patients with more than 2 years of
follow-up). Data were analysed with STATA software ver-
sion 11.0 (Stata Corporation, College Station, TX, USA).
Results
Overall, 20 hospitals reported at least one case. Among 30
CE cases, 29 were definite and one was possible (patient
no. 23, with valvular bioprostheses and eight positive blood
cultures but no vegetation at TEE or any septic phlebitis or
metastatic complication).
Patient characteristics, and clinical and biological findings
Demographic and clinical characteristics of the 30 CE
patients are shown in Tables 1 and 2. The median time
between the first fungaemic episode and diagnosis of CE was
5 days (range, 1 day to 2 months). The significant differences
between intravenous drug users and non-users are shown in
Table 3. Only three patients from this latter group had com-
munity-acquired endocarditis. Eight patients experienced
prior endocarditis; the median intervals between the
previous episode and current CE were 1.5 years (range,
15 days to 10 years) for seven of them with prior bacterial
endocarditis, and 2 years for patient no. 15, who experi-
enced prior Candida parapsilosis endocarditis. Among ten
(33%) patients with prosthetic valve endocarditis, the interval
between valve replacement and CE was <1 year for five of
ten patients. Eighty-three per cent of patients had an acute
presentation, with a duration of symptoms £6 weeks. Ten
(33%) patients were afebrile. None of the nine drug users
had right-sided endocarditis. Among them, five experienced
prior left-sided endocarditis and four had no known predis-
posing cardiopathy. A skin or catheter-related portal of entry
was found in eight of ten C. parapsilosis complex cases.
Among the 11 of 13 patients with a catheter-related
infection in whom the date of insertion was known, the
median duration between insertion and CE diagnosis was
46 days (range, 7–540 days). Twenty-two patients (73%)
experienced embolic complications, which occurred under
medical treatment in three of them. All patients were human
immunodeficiency virus-negative.
Echocardiographic findings
TEE was performed in 27 patients (90%); the three remaining
patients only had transthoracic echocardiography performed.
A description of cardiac involvement is given in Tables 1 and
2. The aortic valve was predominantly involved (n = 16/30
cases; 53%). In half of the cases, the vegetation size was
>13 mm.
Mycological findings
Susceptibility testing. The Candida species responsible for
endocarditis were distributed as follows: 11 Candida albicans,
ten C. parapsilosis complex (nine C. parapsilosis and one Can-
dida orthopsilosis), three Candida tropicalis, two Candida guillier-
mondii, two Candida glabrata, one Candida kefyr, and one
Candida pelliculosa. Blood cultures were positive in 28 of 30
(93%) cases. For the remaining two patients (nos. 30 and 5),
diagnosis was based on valve or embolic tissue culture
results. For all of the isolates tested (n = 29), MIC values
were less than or equal to the MIC90 for all species except
for one C. parapsilosis isolate with a fluconazole MIC of
8 mg/mL, one C. albicans isolate with a flucytosine MIC of
4 mg/mL, and one C. guilliermondii isolate with a voriconazole
MIC of 0.5 mg/mL.
Diagnostic performances of (1,3)-b-D-glucans, mannan and anti-
mannan antibodies, and molecular tools on blood samples. The
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quantity and quality of blood samples allowed serological
investigations in 18 of 30 patients and molecular investiga-
tions in 12 of them.
For serological investigations, 68 sera were available for
these 18 patients. Table 2 indicates the number of positive
results for each fungal antigen tested. Overall, all patients
tested had at least one positive test result: mannan/anti-man-
nan antibodies and (1,3)-b-D-glucans were detected in 15 of
18 (83%) and 18 of 18 (100%) patients, respectively. False-
negative mannan/anti-mannan antibody detection occurred
only in patients infected with C. parapsilosis complex. Of 16
of 18 patients who had at least two serum samples collected,
all had at least two consecutive positive (1,3)-b-D-glucan
results and 13 (81%) had at least two consecutive positive
anti-mannan antibody and/or mannanaemia results. (1,3)-b-D-
Glucan serum levels were significantly higher in patients
infected with C. parapsilosis complex, C. tropicalis and C. guil-
liermondii than in patients infected with C. albicans (p <0.002)
(Fig. 1). In 15 of 18 patients, (1,3)-b-D-glucans persisted for
at least 3 weeks after the diagnosis of CE, but no clear rela-
tionship between the persistence of (1,3)-b-D-glucans and
outcome was established.
For molecular investigations on blood, 48 samples were
available from 12 patients (median, 4; range, 3–6). Quantita-
tive PCR (qPCR) results remained positive in two patients
(nos. 23 and 18), but with a slight decrease in the fungal bur-
den over time, whereas blood cultures were persistently
positive. For three patients (nos. 3, 21, and 24), only the
day 1 sample was qPCR-positive for the same yeast species
as blood cultures (Table 2). Those three patients underwent
surgery, and the subsequent blood cultures were negative.
For five patients, the first sample was obtained after the initi-
ation of treatment (median, 12 days; range, 2–37 days), and
all were qPCR-negative. For patient no. 26, the qPCR results
were negative, but blood cultures were positive for C. guillier-
mondii, a yeast species not included in the spectrum of the
SeptiFast kit. For the remaining patient (no. 16), the qPCR
result was positive for bacteria only.
Valve investigations. Samples from 13 patients were analysed;
12 were obtained during surgery and one at autopsy. Cul-
tures of the surgical cardiac material were positive in nine of
12 samples, all obtained within the first 3 weeks following
diagnosis (Table 2). All three culture-negative samples were
obtained from patients who had valvular surgery ‡1 month
after diagnosis. A total of eight of 13 samples were submit-
ted for histopathology, and all showed histology compatible
with endocarditis, with yeasts being identified in six of eight
samples. In three cases, thrombi without valvular tissue were
analysed, and consisted mainly of fibrin and leukocytes. The
TABLE 1. Clinical characteristics and outcome in 30
patients with Candida endocarditis (CE)
Characteristics No. (%)
Age (years), median (range) 57 (6–82)
Male 24 (80)
Community-acquired CE 12 (40)
Healthcare-associated CE 18 (60)
Host predisposing conditionsa 30 (100)
Central venous access 16 (53)
Malnutrition 13 (43)
Intravenous drug addiction 9 (30)
Solid cancer or haematological malignancy 6 (20)
Parenteral nutrition 5 (17)
Diabetes mellitus 5 (17)
Haemodialysis 4 (13)
Chronic respiratory insufficiency 4 (13)
Chronic renal insufficiency 4 (13)
Congestive heart failure 4 (13)
Chronic alcoholism 2 (7)
Prior solid organ transplantation 1 (3)
Antibiotics (>10 days) within 3 months preceding CEb 13 (48)
Immunosuppressive and/or corticosteroid treatment 6 (20)
Predisposing cardiac diseasec 16 (53)
Valvular prosthesis 10 (33)
Previous episode of infective endocarditis 8 (27)
Pacemaker 2 (7)
Artificial heart 1 (3)
Congenital heart disease 1 (3)
Suspected portal of entry
Central venous access 13 (43)
Skin 8 (27)
Urinary tract 2 (7)
Surgical site infection 1 (3)
Undetermined 6 (20)
Median time to diagnosis (days) (range) 11 (1–90)
Clinical findings
Fever 20 (67)
Septic shock 6 (20)
Cardiac failure 6 (20)
Embolic complications 22 (73)
Spleen/brain/limb/eye/coronary artery/kidney/liver/lung 8/6/6/4/3/3/2/1
Biology
C-reactive protein (mg/L), median (range) 73 (8–301)
Neutrophil count (per mm2), median (range) 6430 (9–34 780)
Echocardiographic abnormalities 28 (93)
Cardiac involvementc
Aortic valve 16 (53)
Mitral valve 12 (40)
Right-sided 2 (7)
Left-sided + right-sided 1 (3)
Pacemaker 2 (7)
Vegetations 27 (90)
Median size (mm) (range) 13 (4–30)
Described as mobile 16 (53)
Annular abscess 5 (17)
Treatment
Antifungal therapy 30 (100)
Caspofungin 23 (77)
Flucytosine 21 (70)
Fluconazole 18 (60)
Voriconazole 9 (30)
Amphotericin B deoxycholate 8 (27)
Liposomal amphotericin B 6 (20)
Antifungal monotherapy 6 (20)
Antifungal combination 24 (80)
Antifungal therapy alone 17 (57)
Combined medical and surgical therapy 13 (43)
Surgery £3 weeks after diagnosis 8 (27)
Outcome
Death 20 (67)
Median time to death (days) (range) 66 (4 days to
6 years)
Cause of death
Related to endocarditis 14 (70)
Consequence of comorbidities 5 (25)
Unknown 1 (5)
aSome patients had more than one predisposing condition.
bn = 27.
cSome patients had more than one cardiac disease/valve involved.
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remaining five cases had valvular biopsy specimens that
revealed extensive inflammation with neutrophils, ulceration,
and necrosis, without fibrosis or calcification. PCR was per-
formed in four cases, and the same species (C. albicans and
C. parapsilosis in two cases each) were identified by pan-fun-
gal PCR and culture. In two additional samples, culture per-
formed in the reporting centre was positive (one
C. pelliculosa and one C. albicans), but the PCR results were
not interpretable, owing to several superimposed sequences.
Culture of the arterial embolus was positive in two of two
samples studied.
Treatment and risk factors for death
The treatment and outcome of the 30 patients are reported
in Tables 1 and 2. Death occurred in 67% (n = 20) patients.
The median time to death after endocarditis diagnosis was
92 days (range, 4 days to 5 years). Eleven patients (37%) died
during the first hospitalization, and nine others died thereaf-
ter. For these latter patients, death was attributable to CE
relapse in four (nos. 1, 12, 14, and 29), to bacterial infection
in two (nos. 2 and 5), and to evolutive underlying disease in
two (nos. 9 and 27), and the cause remained unknown in
patient no. 30, who died suddenly at home. The median fol-
low-up among survivors at hospital discharge was 1 year
(range, 5 months to 4 years). Overall, 13 (43%) patients had
valvular surgery; the most frequent indication for surgery
was ‘embolic’ (n = 7), followed by ‘infectious’ (n = 5) or ‘car-
diac’ (n = 5); four patients had more than one indication.
The death rates were 61.5% (8/13) among operated patients
and 70.6% (12/17) among unoperated patients (p >0.05).
Of the ten patients who survived, five (nos. 3, 10, 15, 21,
and 24) received antifungals in addition to surgery; all of
them were intravenous drug users and had valvular surgery
within 11 days following CE diagnosis. Five patients (nos. 4,
11, 19, 20, and 26) received a combination of antifungals
without surgery; two of them (nos. 4 and 26) with aortic
prostheses are still receiving life-long fluconazole without
recurrence after follow-ups of 2 years and 1 year, respec-
tively. Among the 20 patients who died, eight had surgery
(five later than 3 weeks following diagnosis). Among the 17
non-operated patients, surgery was contraindicated in 13,
owing to poor performance status. Twelve of them died
within a median of 42 days (range, 5–210 days) between CE
diagnosis and death.
The mortality rate was significantly lower in patients
<60 years old than in those ‡60 years old (4/100 person-
months (95% CI 1.9–8.3) and 14.5/100 person-months
(95% CI 8.0–26.2), respectively; p 0.018). After univariate
analysis, an age ‡60 years increased the risk of death,
whereas being an intravenous drug user decreased it. Fig. 2T
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shows the survival curves according to age (i.e. <60 vs.
‡60 years old) and the intravenous drug user status. No
therapeutic option gave a survival benefit (Table 4).
Discussion
Our prospective study provides original data on current
aspects of 30 CE cases in the era of modern diagnostic tools
and new antifungals. Two distinct patient profiles were
observed: a group of young intravenous drug users without
underlying disease, presenting with ‘non-healthcare-associ-
ated’ endocarditis, often having valvular surgery early and
having a low mortality rate; and a group of older patients
(>60 years) with major comorbidities, developing healthcare-
associated endocarditis, often treated with antifungals alone,
and having a worse outcome. Although intravenous drug use
was a risk factor in as many as 36 of 270 patients with CE
[5], this condition has never been identified before as a
parameter of better outcome. As no intravenous drug user
was older than 60 years, it was not possible to know
whether the decreased risk of death associated with drug
use was related to their younger age. It is of note that, in
contrast to a recent Italian series, we did not find a higher
mortality rate among patients with prosthetic valve endocar-
ditis [2].
The classic clinical presentation of CE is a patient with risk
factors for invasive candidiasis that rapidly presents symp-
toms suggestive of embolic complications, leading to the dis-
covery of voluminous left-sided mobile vegetations. The
absence of fever and/or cardiac failure does not exclude the
diagnosis of CE. Considering the severity of CE and the high
frequency of embolic complications, one may wonder
whether systematic TEE should be performed for each fun-
gaemic patient, in order to shorten the time for diagnosis
(Fernandez Cruz et al., 50th ICAAC, 2010, Abstract K-2172).
In addition, as the time between the first fungaemic episode
and diagnosis of CE is sometimes very long, CE should be
suspected and TEE discussed in cases of recurrence of fever
in patients with a past history of fungaemia. Surprisingly,
right-sided involvement is currently rare, even among drug
users [5,25]. The outcome is extremely poor [1,2,5,6,26].
Interpretation of our very high (67%) mortality rate should
take into account the long follow-up period as compared
with most series, which report only in-hospital mortality.
Indeed, only 11 (37%) patients died during the first hospital-
ization. A meta-analysis reviewing the outcome of 72 CE
cases occurring between 1966 and 2002 found a lower pro-
portion of deaths among patients who had valvular surgery
[27]. Among 33 cases derived from the International Collab-
oration of Endocarditis-Prospective Cohort Study, the mor-
tality rate was similar whether surgery was performed or
not [1]. We did not find any difference in prognosis accord-
ing to the management (i.e. medical therapy alone vs. com-
bined with surgery) of CE. [28]. However, our results
suggest that early cardiac surgery during CE should always
be attempted, and only patients with very poor medical sta-
tus might not be operated on. For the latter patients, defini-
tive antifungal therapy can be considered. Overall, 77% of
our patients, and 33.3–66.6% of the cases in two recent
studies [1,2], received caspofungin, in accordance with cur-
rent guidelines [8]. There was a trend towards better out-
come in patients receiving caspofungin at diagnosis, which
may be explained by the activity of caspofungin and other
echinocandins against Candida species producing biofilms,
amphotericin B deoxycholate and azoles not sharing this
TABLE 3. Differences in clinical
characteristics and outcome
between intravenous drug users
and non-intravenous drug users
with Candida endocarditis
Intravenous
drug users
(n = 9)
Non-intravenous
drug users (n = 21)
Total
(N = 30) p-Value
Age (years), median (range) 38 (27–42) 63 (6–82) 57 (6–82) <0.001
Community-acquired infection, no. (%) 9 (100) 3 (14) 12 (40) <0.001
Healthcare-associated infection, no. (%) 0 (0) 18 (86) 18 (60) <0.001
Host predisposing conditions, no. (%)a
Central venous access 0 (0) 16 (76) 16 (53) <0.001
Antibiotics (>10 days) within 3 months
preceding endocarditis
0 (0) 13 (72)b 13 (48)c 0.001
Prior infective endocarditis 5 (56) 3 (14) 8 (27) 0.032
Suspected portal of entry, no (%)
Central venous access 0 (0) 13 (62) 13 (43) 0.003
Skin 8 (89) 0 (0) 8 (27) <0.001
Treatment, no. (%)
Antifungal therapy alone 1 (11) 16 (76) 17 (57) 0.002
Combined medical and surgical therapy 8 (89) 5 (24) 13 (43) 0.002
Surgery £3 weeks after diagnosis 7 (78) 1 (5) 8 (27) <0.001
Death 3 (33) 17 (81) 20 (67) 0.03
aSome patients had more than one predisposing condition.
bn = 18.
cn = 27.
CMI Lefort et al. Candida endocarditis E105
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E99–E109
specificity. In accordance with recent data from France [29]
and elsewhere [30–32], almost two-thirds of our cases were
attributable to non-albicans species.
As CE diagnosis is often delayed, alternative diagnostic
tools needed to be evaluated. We found a positive PCR
result in four of six available tissues, in accordance with pre-
vious reports [33,34]. We also investigated the role of fungal
DNA detection with a commercially available assay [35–37].
When positive, the qPCR results correlated with those of
blood cultures and the yeast species identification. Whether
or not qPCR can provide additional clues for the treatment
efficacy evaluation as compared with blood cultures warrants
specific study.
A recent compilation of data regarding the use of mannan/
anti-mannan antibody detection showed that it had a high
negative predictive value [38]. In our study, the classic lack
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FIG. 1. Distribution of circulating (1,3)-b-D-glucans (s (a)) and anti-mannan antibody levels (s (b)) in 68 serum samples from 18 patients with
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of mannan detection, mainly during C. parapsilosis episodes,
was compensated for by the detection of high levels of anti-
mannan antibodies. Despite the variability in mannan/anti-
mannan antibody and (1,3)-b-D-glucan serum levels between
patients, all patients with definite CE had positive results
with at least one of the two tests at the time of CE diagno-
sis. This suggests that, in patients with negative detection of
(1,3)-b-D-glucans and mannan/anti-mannan antibodies, the
diagnosis of CE is probably unlikely, although we only evalu-
ated patients with positive blood cultures. Interestingly, high
levels of (1,3)-b-D-glucans persisted for several weeks. These
results mean that (1,3)-b-D-glucan levels increase during the
early phase of the disease but do not always return to base-
line during the early period of antifungal treatment, as
recently observed in haematopoietic stem cell transplantation
recipients with candidaemia [39]. Complementarity of (1,3)-
b-D-glucans, mannan/anti-mannan antibodies and Candida
DNAaemia was made apparent here. However, because of
the lack of subsequent blood samples, no definite conclusion
can be drawn regarding the impact of antifungal treatment
on these parameters.
Although prospective, our study has some limitations.
First, the rarity of the disease precludes a multivariate
analysis of risk factors for death. Second, complications may
be underestimated, as imaging explorations were not
performed systematically in the absence of clinical symptoms
[40]. Third, all therapeutic decisions were made by the
physicians in charge of the patient, which obviously
introduces heterogeneity in the management of CE. Finally,
we were unable to measure the contribution of serum
antigen detection and molecular tools in the diagnosis of
CE, as all patients had a diagnosis of endocarditis at
inclusion. However, we collected prospective data that pro-
vide useful information for accurate clinical decision-making
during CE.
In conclusion, CE remains a severe infection with frequent
embolic complications and a high mortality rate. The progno-
sis in younger patients and intravenous drug users is better
than in older patients with healthcare-related infections.
Serum markers and molecular tools may help in optimizing
the diagnosis and management of CE.
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